Market Research Logo

Global Alzheimer’s Disease Therapeutics And Diagnostics Market Forecast 2018-2026

Global Alzheimer’s Disease Therapeutics And Diagnostics Market Forecast 2018-2026

KEY FINDINGS

The rise in the prevalence of Alzheimer’s disease in the ever-growing geriatric population and increasing healthcare expenditure are chiefly responsible for driving the global market for Alzheimer’s disease diagnostic and therapeutics over the forecast period of 2018-2026. The market is likely to exhibit a CAGR of 7.50% during this period.

MARKET INSIGHTS

The global Alzheimer’s disease therapeutics and diagnostics market is segmented on the basis of therapeutics and diagnostics. The therapeutics segment further includes generic and branded therapeutics, therapeutic drugs and therapeutics by disease stage. The Diagnostics segment of the market is further divided into lumbar puncture test, positron emission tomography, electroencephalography, magnetic resonance imaging, computed tomography and other diagnostics

REGIONAL INSIGHTS

The regional segmentation of the global Alzheimer’s disease therapeutics and diagnostic market is done into Europe, North America, Asia-Pacific and rest of the world. Of these, North America is the strongest market for Alzheimer disease therapeutics and diagnostics. New therapies are gaining market approval in this region which is anticipated to boost the sales in this market. Also, the Asia-Pacific is a significant market for Alzheimer’s disease therapeutics and diagnostics. Japan, China and India are the key contributing markets in this region.

COMPETITIVE INSIGHTS

Market players like Amarantus Bioscience Holdings Inc, Abbvie Inc, Axon Neuroscience Se, Biogen Inc, Baxter International Inc, Cognoptix Inc, F. Hoffmann-La Roche Ag, Diagenic Asa,Ge Healthcare, Pfizer Inc, Merck And Co, Piramal Enterprises Ltd, Sun Pharma and Siemens Medical Solutions are dominating the global market.


1. Research Scope
1.1. Study Goals
1.2. Scope Of The Market Study
1.3. Who Will Find This Report Useful?
1.4. Study And Forecasting Years
2. Research Methodology
2.1. Sources Of Data
2.1.1. Secondary Data
2.1.2. Primary Data
2.2. Top Down Approach
2.3. Bottom-up Approach
2.4. Data Triangulation
3. Executive Summary
3.1. Market Summary
3.2. Key Findings
3.2.1. Computed Tomography Is Majorly Used In The Diagnostics Of Alzheimer’s Disease
3.2.2. Therapeutics Market Constitutes The Largest Market Share
3.2.3. North America Is A Market Leader For Alzheimer’s Disease Diagnostic And Therapeutic Market
4. Market Determinants
4.1. Market Drivers
4.1.1. Growing Geriatric Population
4.1.2. Rise In The Pervasiveness Of Alzheimer’s Disease
4.1.3. Increasing Healthcare Expenditure
4.1.4. Government Investment In Research And Development
4.2. Market Restraints
4.2.1. Stringent Government Regulations
4.2.2. High Cost Of Therapies Used For The Treatment Of Alzheimer’s Disease
4.3. Market Opportunities
4.3.1. Advancements In In-vitro Diagnostic Techniques
4.3.2. Increasing R&D Investment In Personalized Medicines
4.4. Market Challenges
4.4.1. Lack Of Skilled Medicinal Practitioners Fot The Treatment Of Alzheimer’s Disease
4.4.2. Dearth Of Awareness Concerning New Therapies In The Alzheimer’s Disease
5. Market Segmentation
5.1. Market By Therapeutics And Diagnostic 2018-2026
5.1.1. Therapeutics
5.1.1.1. Therapeutics By Drugs
5.1.1.1.1. Marketed Drugs
5.1.1.1.2. Pipeline Drugs
5.1.1.2. Therapeutics By Disease Stage
5.1.1.2.1. Late Stage: Severe Ad
5.1.1.2.2. Early/Middle Stage: Mild To Moderate Ad
5.1.1.2.3. Prodromal Stage
5.1.1.3. Therapeutics By Generic And Branded
5.1.1.3.1. Branded
5.1.1.3.2. Generic
5.1.2. Diagnostics
5.1.2.1. Lumbar Puncture Test
5.1.2.2. Positron Emission Tomography
5.1.2.3. Electroencephalography
5.1.2.4. Magnetic Resonance Imaging
5.1.2.5. Computed Tomography
5.1.2.6. Other Diagnostics
6. Key Analytics
6.1. Porter’s Five Force Model
6.1.1. Threat Of New Entrants
6.1.2. Threats Of Substitute Product
6.1.3. Bargaining Power Of Buyer
6.1.4. Bargaining Power Of Supplier
6.1.5. Intensity Of Competitive Rivalry
6.2. Key Buying Criteria
6.2.1. Price
6.2.2. Efficiency
6.2.3. Safety
6.3. Etymology Of Alzheimer’s Disease Therapeutics And Diagnostics Market
6.4. Parent Market Analysis
6.5. Investments Analysis
6.5.1. Research And Development
6.5.2. Raw Materials
6.5.3. Manufacturing
6.5.4. Wholesalers
6.5.5. End User
6.6. Regulatory Framework
6.7. The United States And Europe Regulatory Agency
6.8. Alzheimer's Disease Etiology
6.9. Phases And Sternness Of Alzheimer’s Disease
6.10. Pipeline Analysis
6.11. Companion Diagnostics
7. Geographical Analysis
7.1. North America
7.1.1. The United States
7.1.2. Canada
7.2. Europe
7.2.1. The United Kingdom
7.2.2. France
7.2.3. Germany
7.2.4. Spain
7.2.5. Rest Of Europe
7.3. Asia Pacific
7.3.1. China
7.3.2. India
7.3.3. Japan
7.3.4. Australia
7.3.5. Rest Of Asia Pacific
7.4. Rest Of World
7.4.1. Latin America
7.4.2. Middle East & Africa
8. Company Profiles
8.1. Competitive Landscape
8.1.1. Market Share Analysis
8.2. Abbvie Inc.
8.2.1. Company Overview
8.2.2. Product Portfolio
8.2.3. Scot Analysis
8.2.4. Strategic Initiatives
8.3. Amarantus Bioscience Holdings, Inc.
8.3.1. Company Overview
8.3.2. Product Portfolio
8.3.3. Scot Analysis
8.3.4. Strategic Initiatives
8.4. Axon Neuroscience Se
8.4.1. Company Overview
8.4.2. Product Portfolio
8.4.3. Scot Analysis
8.4.4. Strategic Initiative
8.5. Baxter International Inc.
8.5.1. Company Overview
8.5.2. Product Portfolio
8.5.3. Scot Analysis
8.6. Biogen Inc.
8.6.1. Company Overview
8.6.2. Product Portfolio
8.6.3. Scot Analysis
8.6.4. Strategic Initiatives
8.7. Cognoptix Inc.
8.7.1. Company Overview
8.7.2. Product Portfolio
8.7.3. Scot Analysis
8.7.4. Strategic Initiatives
8.8. Diagenic Asa
8.8.1. Company Overview
8.8.2. Product Portfolio
8.8.3. Scot Analysis
8.9. F. Hoffmann-la Roche Ag
8.9.1. Company Overview
8.9.2. Product Portfolio
8.9.3. Scot Analysis
8.9.4. Strategic Initiatives
8.10. Ge Healthcare
8.10.1. Company Overview
8.10.2. Product Portfolio
8.10.3. Scot Analysis
8.10.4. Strategic Initiatives
8.11. Merck And Co.
8.11.1. Company Overview
8.11.2. Product Portfolio
8.11.3. Scot Analysis
8.11.4. Strategic Initiatives
8.12. Pfizer Inc.
8.12.1. Company Overview
8.12.2. Product Portfolio
8.12.3. Scot Analysis
8.12.4. Strategic Analysis
8.13. Piramal Enterprises Ltd.
8.13.1. Company Overview
8.13.2. Product Portfolio
8.13.3. Scot Analysis
8.13.4. Strategic Initiatives
8.14. Siemens Medical Solutions
8.14.1. Company Overview
8.14.2. Product Portfolio
8.14.3. Scot Analysis
8.14.4. Strategic Initiatives
8.15. Sun Pharma
8.15.1. Company Overview
8.15.2. Product Portfolio
8.15.3. Scot Analysis
8.15.4. Strategic Initiatives
Table List
Table 1 Global Alzheimer’s Disease Therapeutics And Diagnostics Market By Geography 2018-2026 ($ Million)
Table 2 Pharmacological Treatment Of Behavioral And Psychological Symptoms Of Dementia (Bpsd) Of Alzheimer's
Table 3 Different Biomarkers Related To The Alzheimer’s Disease
Table 4 Global Alzheimer’s Disease Therapeutics And Diagnostics Market 2018-2026 ($ Million)
Table 5 Global Alzheimer’s Disease Therapeutics And Diagnostics Market In Therapeutics By Drugs 2018-2026 ($ Million)
Table 6 Global Alzheimer’s Disease Therapeutics Market In Marketed Drugs By Geography 2018-2026 ($ Million)
Table 7 Global Alzheimer’s Disease Therapeutics Market In Pipeline Drugs By Geography 2018-2026 ($ Million)
Table 8 Global Alzheimer’s Disease Therapeutics And Diagnostics Market In Disease Stage By Drugs 2018-2026 ($ Million)
Table 9 Global Alzheimer’s Disease Therapeutics Market In Late Stage: Severe Ad By Geography 2018-2026 ($ Million)
Table 10 Global Alzheimer’s Disease Therapeutics Market In Early/Middle Stage: Mild To Moderate Ad By Geography 2018-2026 ($ Million)
Table 11 Global Alzheimer’s Disease Therapeutics Market In Prodromal Stage By Geography 2018-2026 ($ Million)
Table 12 Global Alzheimer’s Disease Therapeutics And Diagnostics Market In Therapeutics By Generic And Branded 2018-2026 ($ Million)
Table 13 Global Alzheimer’s Disease Therapeutics Market In Branded By Geography 2018-2026 ($ Million)
Table 14 Global Alzheimer’s Disease Therapeutics Market In Generic By Geography 2018-2026 ($ Million)
Table 15 Global Alzheimer’s Disease Therapeutics And Diagnostics Market By Types 2018-2026 ($ Million)
Table 16 Global Alzheimer’s Disease Diagnostics Market In Lumbar Puncture Test By Geography 2018-2026 ($ Million)
Table 17 Global Alzheimer’s Disease Diagnostics Market In Positron Emission Tomography By Geography 2018-2026 ($ Million)
Table 18 Global Alzheimer’s Disease Diagnostics Market In Electroencephalography By Geography 2018-2026 ($ Million)
Table 19 Global Alzheimer’s Disease Diagnostics Market In Magnetic Resonance Imaging By Geography 2018-2026 ($ Million)
Table 20 Global Alzheimer’s Disease Diagnostics Market In Computed Tomography By Geography 2018-2026 ($ Million)
Table 21 Global Alzheimer’s Disease Diagnostics Market In Other Diagnostics By Geography 2018-2026 ($ Million)
Table 22 Global Alzheimers Disease Therapeutics And Diagnostic Market By Geography 2018-2026
Table 23 North America Alzheimers Disease Therapeutics And Diagnostic Market 2018-2026
Table 24 Europe Alzheimers Disease Therapeutics And Diagnostic Market 2018-2026
Table 25 Asia Pacific Alzheimers Disease Therapeutics And Diagnostic Market 2018-2026
Table 26 Asia Pacific Alzheimers Disease Therapeutics And Diagnostic Market 2018-2026
Table 27 Rest Of World Alzheimers Disease Therapeutics And Diagnostic Market 2018-2026
Figures List
Figure 1 Global Alzheimer’s Disease Therapeutics And Diagnostics Market 2018-2026 ($ Million)
Figure 2 People Suffering From Alzheimer’s Dementia In The United States Of Different Ages 2017 (%)
Figure 3 Rising Health Expenditure In The United States ($ Per Capita)
Figure 4 Costs Of Care For People With Alzheimer’s And Other Dementias 2017 ($ Billion)
Figure 5 Global Alzheimer’s Disease Therapeutics And Diagnostics Market In Therapeutics 2018-2026 ($ Million)
Figure 6 Global Alzheimer’s Disease Therapeutics And Diagnostics Market In Diagnostics2018-2026 ($ Million)
Figure 7 Investments In Alzheimer’s Disease Treatment
Figure 8 Alzheimer's Drugs In The Pipeline By Treatment Focus (Number Of Drugs)
Figure 9 Global Clinical Trials On Alzheimer's Drug By Mechanism Of Action (%)
Figure 10 Fda-approved Cdx-drug Pairs By Molecular Target
Figure 11 The United States Alzheimers Disease Therapeutics And Diagnostic Market 2018-2026
Figure 12 Canada Alzheimers Disease Therapeutics And Diagnostic Market 2018-2026
Figure 13 Europe Alzheimers Disease Therapeutics And Diagnostic Market 2018-2026
Figure 14 The United Kingdom Alzheimers Disease Therapeutics And Diagnostic Market 2018-2026
Figure 15 France Alzheimers Disease Therapeutics And Diagnostic Market 2018-2026
Figure 16 Germany Alzheimers Disease Therapeutics And Diagnostic Market 2018-2026
Figure 17 Spain Alzheimers Disease Therapeutics And Diagnostic Market 2018-2026
Figure 18 Rest Of Europe Alzheimers Disease Therapeutics And Diagnostic Market 2018-2026
Figure 19 China Alzheimers Disease Therapeutics And Diagnostic Market 2018-2026
Figure 20 India Alzheimers Disease Therapeutics And Diagnostic Market 2018-2026
Figure 21 Japan Alzheimers Disease Therapeutics And Diagnostic Market 2018-2026
Figure 22 Australia Alzheimers Disease Therapeutics And Diagnostic Market 2018-2026
Figure 23 Rest Of Asia Pacific Alzheimers Disease Therapeutics And Diagnostic Market 2018-2026
Figure 24 Rest Of World Alzheimers Disease Therapeutics And Diagnostic Market 2018-2026
Figure 25 Latin America Alzheimers Disease Therapeutics And Diagnostic Market 2018-2026
Figure 26 Middle East & Africa Alzheimers Disease Therapeutics And Diagnostic Market 2018-2026
Figure 27 Market Share Analysis Of Alzheimer’s Disease Therapeutics And Diagnostics Market 2017 (%)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report